Status:

WITHDRAWN

iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma

Lead Sponsor:

City of Hope Medical Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Renal Cell Carcinoma

Eligibility:

All Genders

18+ years

Brief Summary

This trial investigates whether an online intervention, iConquerFear, can reduce fear of cancer coming back (recurrence) and anxiety in patients with renal cell carcinoma that is restricted to the sit...

Detailed Description

PRIMARY OBJECTIVES: I. To assess feasibility and acceptability of the iConquerFear program for patients with renal cell carcinoma (RCC). II. To assess preliminary effects of the program on Fear of C...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Sufficiently fluent in English
  • Cytologically or pathologically verified diagnosis of RCC
  • Undergone nephrectomy with negative margins (NOTE: Patients with other local definitive therapies, e.g., radiofrequency ablation or stereotactic ablative radiotherapy \[SABR\], would not be candidates for this protocol)
  • No evidence of metastatic disease (including at a minimum computed tomography \[CT\] of the chest, abdomen and pelvis for staging)
  • Internet access and basic computer skills
  • Moderate to severe fear of cancer recurrence (FCR)

Exclusion

    Key Trial Info

    Start Date :

    August 20 2022

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    August 27 2023

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT04688333

    Start Date

    August 20 2022

    End Date

    August 27 2023

    Last Update

    June 26 2025

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.